Please login to the form below

Not currently logged in
Email:
Password:

Abbott's paediatric HIV drug wins FDA approval

US-based pharmaceutical company Abbott wins FDA approval for its lower-strength protease-inhibitor Kaletra, which will be available in the US from November 2007

US-based pharmaceutical company Abbott has won FDA approval for its lower-strength protease-inhibitor Kaletra (lopinavir/ritonavir), which will be available in the US from November 2007.

The new lower-strength tablets are smaller in size than original Kaletra tablets and contain the same proven active ingredients as Abbott's Kaletra oral solution. The lower-strength Kaletra tablet is approved for children weighing 15 kg or more who are able to swallow the intact tablet.

Scott Brun, divisional vice-president of infectious diseases and renal development at Abbott's global pharmaceutical R&D arm, said: "HIV/AIDS continues to have a devastating impact globally, especially among the more than two million children living with the disease throughout the world. Abbott developed a lower-strength tablet formulation of Kaletra to give doctors an innovative treatment option to help curb the impact of HIV infection in children."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics